Information about the 2019 Novel Coronavirus
Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidol Oral Solution for Treatment of Lennox-Gastaut Syndrome
Trial ID or NCT#
This Phase 3 trial will enroll participants diagnosed with Lennox-Gastaut Syndrome (LGS) who are still experiencing at least 4 motor seizures involving the trunk or extremities per week, despite ongoing treatment with up to 3 antiepileptic drugs (AEDs) and who meet inclusion/exclusion criteria.
Following a 28-day baseline period, subjects will begin an 84-day treatment period. Participants will be assigned to receive twice daily doses of placebo or cannabidiol oral solution at the highest dose determined to be safe in a previous trial.
Following study completion, all subjects will be invited to receive Cannabidiol Oral Solution in an open label extension study (under a separate protocol).
Contact us to find out if this trial is right for you.
About this Clinical Trial
A Multicenter Randomized Double Blind Placebo Controlled Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidol Oral Solution as an Adjunctive Therapy for Treatment of Subjects with Inadequetely Controlled Lennox-Gastaut Syndrome
Your Message Will Go ToMaria Coburn
Go Back To The Trial